NG,NG-dimethyl-L-Arginine (hydrochloride)
(Synonyms: 不对称二甲基精氨酸二盐酸盐溶液,100PPM,ADMA) 目录号 : GC17237An endogenous NOS inhibitor
Cas No.:220805-22-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
NG,NG-dimethyl-L-Arginine is an endogenous nitric oxide synthase inhibitor.
Nitric oxide (NO) that is synthesised from L-arginine contributes to the regulation of blood pressure and to host defence.
In vitro: NG,NG-dimethyl-L-Arginine (ADMA) was found to be able to inhibit macrophage and vascular NO synthase. When added to a cytosolic preparation of macrophage NO synthase, ADMA could cause dose-dependent inhibition of NO formation. In the presence of added arginine, ADMA could inhibited NO synthesis and the inhibitory effects of ADMA were prevented by addition of L-arginine so that the rate of NO synthesis did not significantly differ from control values [1].
In vivo: Animal study showed that the injection of 1-30 mg/kg ADMA into 3 anaesthetised guineapigs could cause dose-dependent increases in mean arterial blood pressure. Moreover, during continuous infusion of ADMA, which caused plasma ADMA concentrations to rise approximately 9-fold, the systolic blood pressure was raised by nearly 15 % [1].
Clinical trial: Local infusion of ADMA into the brachial artery of healthy volunteers caused a dose-dependent fall in forearm blood-flow. Infusion of ADMA for 5 min resulted in a fall in forearm blood-flow in 5 subjects, and the effects of this ADMA dose were significantly attenuated by infusion of L-arginine [1].
Reference:
[1] Vallance, P. ,Leone, A.,Calver, A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575 (1992).
Cas No. | 220805-22-1 | SDF | |
别名 | 不对称二甲基精氨酸二盐酸盐溶液,100PPM,ADMA | ||
化学名 | N5-[(dimethylamino)iminomethyl]-L-ornithine, dihydrochloride | ||
Canonical SMILES | OC(=O)[C@@H](N)CCCNC(=N)N(C)C | ||
分子式 | C8H18N4O2 • 2HCl | 分子量 | 275.2 |
溶解度 | DMF: 5 mg/ml; DMSO: 3 mg/ml; Ethanol: 3 mg/ml; PBS (pH 7.2): 20 mg/ml; Water: 20 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.6337 mL | 18.1686 mL | 36.3372 mL |
5 mM | 0.7267 mL | 3.6337 mL | 7.2674 mL |
10 mM | 0.3634 mL | 1.8169 mL | 3.6337 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。